DK1951729T3 - Oxygenbundne pyrimidinderivater - Google Patents

Oxygenbundne pyrimidinderivater

Info

Publication number: DK1951729T3
Authority: DK; Denmark
Prior art keywords: compounds; pyrimidine derivatives; oxygen bonded; useful; treatment
Prior art date: 2005-11-16

Application number

DK06813132.5T

Other languages

English (en)

Inventor

Stéphanie Blanchard

Cheng Hsia Angeline Lee

Harish Kumar Mysore Nagaraj

Yee Ling Evelyn Tan

Eric T Sun

Anthony Deodaunia William

Anders Poulsen

Original Assignee

Cti Biopharma Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-16

Filing date

2006-11-15

Publication date

2014-10-06

2006-11-15 Application filed by Cti Biopharma Corp filed Critical Cti Biopharma Corp

2014-10-06 Application granted granted Critical

2014-10-06 Publication of DK1951729T3 publication Critical patent/DK1951729T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/06—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/16—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Neurology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Hospice & Palliative Care (AREA)
Oncology (AREA)
Diabetes (AREA)
Urology & Nephrology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Solid-Sorbent Or Filter-Aiding Compositions (AREA)

DK06813132.5T 2005-11-16 2006-11-15 Oxygenbundne pyrimidinderivater DK1951729T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US73683805P	2005-11-16	2005-11-16
US81733906P	2006-06-30	2006-06-30
US85128306P	2006-10-13	2006-10-13
PCT/SG2006/000352 WO2007058627A1 (en)	2005-11-16	2006-11-15	Oxygen linked pyrimidine derivatives

Publications (1)

Publication Number	Publication Date
DK1951729T3 true DK1951729T3 (da)	2014-10-06

Family

ID=38048928

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK06813132.5T DK1951729T3 (da)	2005-11-16	2006-11-15	Oxygenbundne pyrimidinderivater
DK06813133.3T DK1951730T3 (da)	2005-11-16	2006-11-15	Heteroalkylbundne pyrimidinderivater

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK06813133.3T DK1951730T3 (da)	2005-11-16	2006-11-15	Heteroalkylbundne pyrimidinderivater

Country Status (20)

Country	Link
US (5)	US8143255B2 (da)
EP (1)	EP1951729B1 (da)
JP (2)	JP5380073B2 (da)
KR (5)	KR101568801B1 (da)
CN (2)	CN101360751B (da)
AT (1)	ATE469158T1 (da)
AU (2)	AU2006316072B2 (da)
BR (1)	BRPI0618552B8 (da)
CA (2)	CA2629443C (da)
CY (1)	CY1116156T1 (da)
DE (1)	DE602006014579D1 (da)
DK (2)	DK1951729T3 (da)
ES (2)	ES2346791T3 (da)
HK (2)	HK1123282A1 (da)
MY (1)	MY148072A (da)
NZ (1)	NZ568325A (da)
PL (1)	PL1951729T3 (da)
PT (2)	PT1951730E (da)
TW (3)	TWI525096B (da)
WO (2)	WO2007058628A1 (da)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005058913A1 (en)	2003-12-18	2005-06-30	Janssen Pharmaceutica N.V.	Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
JO3088B1 (ar) *	2004-12-08	2017-03-15	Janssen Pharmaceutica Nv	مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
NI200700147A (es)	2004-12-08	2019-05-10	Janssen Pharmaceutica Nv	Derivados de quinazolina inhibidores de cinasas dirigidos a multip
US8604042B2 (en)	2005-11-01	2013-12-10	Targegen, Inc.	Bi-aryl meta-pyrimidine inhibitors of kinases
BR122021011787B1 (pt)	2005-11-01	2022-01-25	Impact Biomedicines, Inc	Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
US8133900B2 (en)	2005-11-01	2012-03-13	Targegen, Inc.	Use of bi-aryl meta-pyrimidine inhibitors of kinases
US10517876B2 (en) *	2005-11-16	2019-12-31	Cti Biopharma Corp.	Oxygen linked pyrimidine derivatives
AR061185A1 (es)	2006-05-26	2008-08-13	Chugai Pharmaceutical Co Ltd	Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas.
US8492377B2 (en)	2006-07-13	2013-07-23	Janssen Pharmaceutica Nv	MTKI quinazoline derivatives
AR065583A1 (es) *	2007-03-01	2009-06-17	Chugai Pharmaceutical Co Ltd	Compuestos macrociclicos y composicion farmaceutica
WO2008140420A2 (en) *	2007-05-15	2008-11-20	S*Bio Pte Ltd	Pyrimidine derivatives
WO2008140419A2 (en) *	2007-05-15	2008-11-20	S*Bio Pte Ltd	Pyridyl substituted pyrimidine derivatives
AU2008274941A1 (en) *	2007-07-12	2009-01-15	Tragara Pharmaceuticals, Inc.	Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
DK2185562T3 (da)	2007-07-27	2016-02-22	Janssen Pharmaceutica Nv	Pyrrolopyrimidiner, som er egnede til behandling af proliferative sygdomme
ES2424982T3 (es) *	2008-03-10	2013-10-10	Janssen Pharmaceutica, N.V.	4-Aril-2-anilino-pirimidinas como inhibidores de cinasas PLK
WO2009132202A2 (en)	2008-04-24	2009-10-29	Incyte Corporation	Macrocyclic compounds and their use as kinase inhibitors
AU2009325147B2 (en) *	2008-12-11	2014-08-14	Cti Biopharma Corp.	11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)] heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt
US8987243B2 (en) *	2008-12-11	2015-03-24	Cti Biopharma Corp.	11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-maleate salt
PT2454266E (pt) *	2009-07-15	2013-10-10	Cell Therapeutics Inc	Sal de citrato de 9e-15-(2-pirrolidin-1-il-etoxi)- 7,12,25-trioxa-19,21,24-triaza-tetraciclo- [18.3.1.1(2,5).1(14)18)]hexacosa- 1(24),2,4,9,14,16,18(26),20,22-nonaeno
UA115523C2 (uk) *	2010-02-05	2017-11-27	Общєство С Огранічєнной Отвєтствєнностью "Новамєдіка"	Тверді форми макроциклічних інгібіторів кінази
TW201206946A (en) *	2010-07-15	2012-02-16	Bristol Myers Squibb Co	Compounds for the reduction of beta-amyloid production
AU2010363329A1 (en)	2010-11-07	2013-05-09	Targegen, Inc.	Compositions and methods for treating myelofibrosis
CN102127087B (zh) *	2011-01-21	2012-07-04	江苏先声药物研究有限公司	喹唑啉衍生物
CN102757448B (zh) *	2011-04-26	2016-04-06	中南大学	大环类激酶抑制剂化合物、制备方法及其作为药物的应用
BR112014007654A8 (pt) *	2011-09-30	2018-06-12	Ipsen Pharma	Inibidores de lrrk2 quinase macrocíclicos.
WO2013059634A1 (en)	2011-10-20	2013-04-25	The Regents Of The University Of California	Use of cdk9 inhibitors to reduce cartilage degradation
CN102617599B (zh) *	2012-04-10	2014-04-16	江苏先声药物研究有限公司	大环类化合物及其应用
WO2014159511A1 (en) *	2013-03-14	2014-10-02	Concert Pharmaceuticals, Inc.	Deuterated pacritinib
CN105164136B (zh) *	2013-05-06	2017-12-22	默克专利股份公司	作为激酶抑制剂的大环化合物
MA39822A (fr) *	2014-04-03	2018-02-06	Janssen Pharmaceutica Nv	Dérivés de pyrimidine bicycle
MA39823A (fr) *	2014-04-03	2018-01-09	Janssen Pharmaceutica Nv	Dérivés de pyridine macrocyclique
RS62713B1 (sr)	2014-08-11	2022-01-31	Acerta Pharma Bv	Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora
TW201618773A (zh)	2014-08-11	2016-06-01	艾森塔製藥公司	Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、及／或ｃｄｋ４／６抑制劑的治療組合物
WO2016024231A1 (en)	2014-08-11	2016-02-18	Acerta Pharma B.V.	Therapeutic combinations of a btk inhibitor, a pi3k inhibitor, a jak-2 inhibitor, a pd-1 inhibitor and/or a pd-l1 inhibitor
FR3025199B1 (fr) *	2014-09-02	2016-09-23	Pf Medicament	Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques
FR3025200B1 (fr) *	2014-09-02	2016-09-23	Pf Medicament	Derives de n-aryl-tricyclopyrimidine-2-amine polyethers macrocycliques
JP2017529365A (ja)	2014-09-17	2017-10-05	オンコデザインエス．ア．	大環状ｌｒｒｋ２キナーゼ阻害剤
JP6930913B2 (ja)	2014-10-14	2021-09-01	ザリージェンツオブザユニバーシティオブカリフォルニアＴｈｅＲｅｇｅｎｔｓＯｆＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＣａｌｉｆｏｒｎｉａ	炎症を阻害するためのｃｄｋ９及びｂｒｄ４阻害剤の使用法
WO2016149031A1 (en) *	2015-03-18	2016-09-22	Newave Pharmaceutical Llc	Covalent inhibitors of cdk-7
CN105017282B (zh) *	2015-08-28	2017-11-07	苏州明锐医药科技有限公司	帕克替尼的制备方法
CN105061467B (zh) *	2015-08-28	2017-08-25	苏州立新制药有限公司	一种帕克替尼的制备方法
ES2973564T3 (es) *	2015-09-28	2024-06-20	Cti Biopharma Corp	Tratamiento o prevención de enfermedad de injerto contra huésped
EP3359544B1 (en) *	2015-10-08	2020-08-12	Bayer Pharma Aktiengesellschaft	Novel modified macrocyclic compounds
KR102491013B1 (ko) *	2016-03-24	2023-01-31	코테라 바이오사이언스 인코포레이티드	Tg02를 사용한 암의 치료
WO2017196261A1 (en) *	2016-05-11	2017-11-16	National University Of Singapore	Jak and hdac dual-inhibitor compounds
ES2977589T3 (es) *	2017-08-18	2024-08-27	Cothera Bioscience Inc	Forma polimórfica de TG02
WO2019079357A1 (en) *	2017-10-17	2019-04-25	Silverback Therapeutics, Inc.	TNIK MODULATORS, CONJUGATES AND USES THEREOF
CN108864145B (zh) *	2018-09-14	2021-03-30	兆科（广州）肿瘤药物有限公司	一种氧联嘧啶衍生物的纯化方法
WO2020097396A1 (en) *	2018-11-07	2020-05-14	Dana-Farber Cancer Institute, Inc.	Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof
CN111269245B (zh) *	2018-12-04	2021-08-27	杭州百新生物医药科技有限公司	一种环状氨基嘧啶衍生物及其抑制激酶的活性和用途
US20220017520A1 (en) *	2018-12-19	2022-01-20	Keythera (Suzhou) Pharmaceuticals Co. Ltd.	Macrocyclic compound as cdk inhibitor, preparation method therefor, and use thereof in medicine
TW202038957A (zh)	2018-12-21	2020-11-01	日商第一三共股份有限公司	抗體-藥物結合物與激酶抑制劑之組合
JP2022529523A (ja) *	2019-04-22	2022-06-22	ユニバーシティオブピッツバーグ－オブザコモンウェルスシステムオブハイヤーエデュケイション	小児対象において神経膠腫を治療するためのｔｇ０２の使用
WO2021091535A1 (en)	2019-11-05	2021-05-14	Constellation Pharmaceuticals, Inc.	Treating myeloproliferative disorders with cpi-0610 and a jak inhibitor
WO2020257644A1 (en)	2019-06-21	2020-12-24	Constellation Pharmaceuticals, Inc.	Methods of treating myeloproliferative disorders
WO2020256739A1 (en)	2019-06-21	2020-12-24	Constellation Pharmaceuticals, Inc.	Methods of treating myeloproliferative disorders
CN112321604A (zh) *	2019-08-05	2021-02-05	华东理工大学	大环类jak2抑制剂及其应用
CN113583020B (zh) *	2020-04-30	2022-04-22	百极弘烨（广东）医药科技有限公司	一种jak2抑制剂及应用
CN113735879B (zh) *	2020-05-27	2022-05-17	百极弘烨（广东）医药科技有限公司	一种大环jak抑制剂及其应用
WO2022056092A1 (en) *	2020-09-11	2022-03-17	Cti Biopharma Corp.	Methods of treating viral infection
CN115490705A (zh) *	2021-06-18	2022-12-20	成都凡诺西生物医药科技有限公司	N-大环酰胺类化合物、其制备方法及其作为药物的应用
CN113603708B (zh) *	2021-07-27	2023-08-11	中国药科大学	一种具有大环骨架结构的cdk9抑制剂的制备及其应用
CN114409674B (zh) *	2022-01-28	2023-07-25	山东大学	一种JAK抑制剂Pacritinib的合成方法
CN117964628A (zh) *	2022-10-24	2024-05-03	科辉智药生物科技(深圳)有限公司	作为cdk9抑制剂的大环类化合物及其应用
CN117447407B (zh) *	2023-12-19	2024-06-11	潍坊医学院	一种JAK2抑制剂Pacritinib及其中间体的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5728536A (en)	1993-07-29	1998-03-17	St. Jude Children's Research Hospital	Jak kinases and regulation of Cytokine signal transduction
US6136595A (en)	1993-07-29	2000-10-24	St. Jude Children's Research Hospital	Jak kinases and regulations of cytokine signal transduction
US5811515A (en)	1995-06-12	1998-09-22	California Institute Of Technology	Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
CA2289709A1 (en)	1997-06-27	1999-01-07	Ciba Specialty Chemicals Holding Inc.	Ruthenium and osmium catalysts
US6608027B1 (en)	1999-04-06	2003-08-19	Boehringer Ingelheim (Canada) Ltd	Macrocyclic peptides active against the hepatitis C virus
US6433018B1 (en)	2001-08-31	2002-08-13	The Research Foundation Of State University Of New York	Method for reducing hypertrophy and ischemia
DE10239042A1 (de) *	2002-08-21	2004-03-04	Schering Ag	Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
ATE552003T1 (de) *	2002-10-29	2012-04-15	Msd Kk	Chinoxalinderivate
WO2004078682A2 (en) *	2003-03-05	2004-09-16	Irm Llc	Cyclic compounds and compositions as protein kinase inhibitors
US7163939B2 (en) *	2003-11-05	2007-01-16	Abbott Laboratories	Macrocyclic kinase inhibitors
US20050096324A1 (en) *	2003-11-05	2005-05-05	Zhi-Fu Tao	Macrocyclic kinase inhibitors
DE602004023876D1 (de) *	2003-12-18	2009-12-10	Janssen Pharmaceutica Nv	3-cyano-chinolin-derivate mit antiproliferativer wirkung
WO2005058913A1 (en) *	2003-12-18	2005-06-30	Janssen Pharmaceutica N.V.	Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
MY169441A (en) *	2004-12-08	2019-04-11	Janssen Pharmaceutica Nv	2,4, (4,6) pyrimidine derivatives
US9047780B2 (en) *	2012-11-16	2015-06-02	Robert Bosch Gmbh	Collision mitigation systems and methods using driver attentiveness

2006
- 2006-11-15 PL PL06813132T patent/PL1951729T3/pl unknown
- 2006-11-15 ES ES06813133T patent/ES2346791T3/es active Active
- 2006-11-15 KR KR1020147003871A patent/KR101568801B1/ko active IP Right Grant
- 2006-11-15 WO PCT/SG2006/000353 patent/WO2007058628A1/en active Application Filing
- 2006-11-15 AT AT06813133T patent/ATE469158T1/de active
- 2006-11-15 PT PT06813133T patent/PT1951730E/pt unknown
- 2006-11-15 US US12/093,874 patent/US8143255B2/en active Active
- 2006-11-15 CN CN2006800506765A patent/CN101360751B/zh active Active
- 2006-11-15 DE DE602006014579T patent/DE602006014579D1/de active Active
- 2006-11-15 JP JP2008541129A patent/JP5380073B2/ja active Active
- 2006-11-15 WO PCT/SG2006/000352 patent/WO2007058627A1/en active Application Filing
- 2006-11-15 JP JP2008541128A patent/JP5225856B2/ja active Active
- 2006-11-15 DK DK06813132.5T patent/DK1951729T3/da active
- 2006-11-15 AU AU2006316072A patent/AU2006316072B2/en active Active
- 2006-11-15 TW TW103101503A patent/TWI525096B/zh active
- 2006-11-15 US US12/093,867 patent/US8153632B2/en active Active
- 2006-11-15 PT PT68131325T patent/PT1951729E/pt unknown
- 2006-11-15 ES ES06813132.5T patent/ES2506040T3/es active Active
- 2006-11-15 KR KR20087013542A patent/KR20080090390A/ko not_active Application Discontinuation
- 2006-11-15 KR KR1020147024470A patent/KR101576159B1/ko active IP Right Grant
- 2006-11-15 BR BRPI0618552A patent/BRPI0618552B8/pt active IP Right Grant
- 2006-11-15 DK DK06813133.3T patent/DK1951730T3/da active
- 2006-11-15 CA CA2629443A patent/CA2629443C/en active Active
- 2006-11-15 TW TW095142296A patent/TWI506029B/zh active
- 2006-11-15 CN CN2006800506549A patent/CN101365703B/zh active Active
- 2006-11-15 NZ NZ568325A patent/NZ568325A/en unknown
- 2006-11-15 CA CA2629455A patent/CA2629455C/en active Active
- 2006-11-15 MY MYPI20081674 patent/MY148072A/en unknown
- 2006-11-15 AU AU2006316071A patent/AU2006316071B2/en active Active
- 2006-11-15 TW TW95142288A patent/TWI407961B/zh active
- 2006-11-15 KR KR1020147003872A patent/KR101513492B1/ko active IP Right Grant
- 2006-11-15 KR KR1020087013543A patent/KR101499594B1/ko active IP Right Grant
- 2006-11-15 EP EP06813132.5A patent/EP1951729B1/en active Active
2009
- 2009-01-15 HK HK09100412.1A patent/HK1123282A1/xx unknown
- 2009-01-19 HK HK09100507.7A patent/HK1124040A1/xx unknown
2012
- 2012-02-13 US US13/371,837 patent/US9133214B2/en active Active
- 2012-04-04 US US13/438,989 patent/US8415338B2/en active Active
2013
- 2013-02-20 US US13/771,546 patent/US9573964B2/en active Active
2014
- 2014-09-25 CY CY20141100782T patent/CY1116156T1/el unknown

Also Published As

Publication number	Publication date
PT1951730E (pt)	2010-08-27
WO2007058627A1 (en)	2007-05-24
EP1951729A1 (en)	2008-08-06
CN101365703A (zh)	2009-02-11
TW200736262A (en)	2007-10-01
US8143255B2 (en)	2012-03-27
AU2006316071A1 (en)	2007-05-24
US9573964B2 (en)	2017-02-21
CA2629455C (en)	2017-01-03
AU2006316072A1 (en)	2007-05-24
KR20080090390A (ko)	2008-10-08
US8415338B2 (en)	2013-04-09
KR20140117679A (ko)	2014-10-07
TWI525096B (zh)	2016-03-11
US8153632B2 (en)	2012-04-10
ES2506040T3 (es)	2014-10-13
JP5380073B2 (ja)	2014-01-08
BRPI0618552A2 (pt)	2011-09-06
PL1951729T3 (pl)	2015-02-27
KR101513492B1 (ko)	2015-04-20
PT1951729E (pt)	2014-10-02
AU2006316072B2 (en)	2011-12-22
US9133214B2 (en)	2015-09-15
US20120196855A1 (en)	2012-08-02
US20090258886A1 (en)	2009-10-15
KR101568801B1 (ko)	2015-11-12
KR20140037257A (ko)	2014-03-26
WO2007058628A1 (en)	2007-05-24
CA2629443C (en)	2016-12-13
TW201418263A (zh)	2014-05-16
CN101365703B (zh)	2013-11-06
TWI506029B (zh)	2015-11-01
EP1951729A4 (en)	2009-09-23
JP5225856B2 (ja)	2013-07-03
CN101360751A (zh)	2009-02-04
CA2629455A1 (en)	2007-05-24
US20120142680A1 (en)	2012-06-07
NZ568325A (en)	2011-05-27
JP2009515954A (ja)	2009-04-16
US20130172338A1 (en)	2013-07-04
MY148072A (en)	2013-02-28
BRPI0618552B8 (pt)	2021-05-25
KR101576159B1 (ko)	2015-12-09
AU2006316071B2 (en)	2011-02-17
KR20140037256A (ko)	2014-03-26
TW200738735A (en)	2007-10-16
ATE469158T1 (de)	2010-06-15
TWI407961B (zh)	2013-09-11
EP1951729B1 (en)	2014-06-25
CN101360751B (zh)	2011-09-14
KR20080086443A (ko)	2008-09-25
HK1123282A1 (en)	2009-06-12
JP2009517344A (ja)	2009-04-30
US20090075999A1 (en)	2009-03-19
KR101499594B1 (ko)	2015-03-09
HK1124040A1 (en)	2009-07-03
DK1951730T3 (da)	2010-09-27
DE602006014579D1 (de)	2010-07-08
ES2346791T3 (es)	2010-10-20
BRPI0618552B1 (pt)	2021-04-06
CY1116156T1 (el)	2017-02-08
CA2629443A1 (en)	2007-05-24

Publication	Publication Date	Title
DK1951729T3 (da)	2014-10-06	Oxygenbundne pyrimidinderivater
HK1145832A1 (en)	2011-05-06	Pyrimidine substituted purine derivatives
MX2009006704A (es)	2009-06-30	Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
WO2010111406A3 (en)	2011-07-07	Purine derivatives useful as anti - cancer agents
EA200901138A1 (ru)	2010-04-30	Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
CL2012003604A1 (es)	2013-03-22	Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
EA200901133A1 (ru)	2010-04-30	Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
TW200724537A (en)	2007-07-01	Pyrimidine derivatives for treatment of hyperproliferative disorders
EA201070327A1 (ru)	2010-08-30	Катехоламиновые производные и их пролекарства
TNSN08370A1 (en)	2009-12-29	Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2009010127A (es)	2009-11-05	Compuestos utiles como inhibidores de janus cinasas.
MX2010006206A (es)	2011-03-04	Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX2008001211A (es)	2008-03-24	Derivados de bencilpiperazina y su uso medico.
SE0300457D0 (sv)	2003-02-19	Novel compounds
WO2008140420A3 (en)	2009-04-30	Pyrimidine derivatives
EP2124554A4 (en)	2009-12-30	COMPOSITIONS AND METHODS FOR CANCER TREATMENT
ATE507218T1 (de)	2011-05-15	Benzodiazepin-derivate als rock-kinasen hemmer
MX2009011576A (es)	2009-11-09	Nuevos derivados de 4,8-difenil-poliazanaftaleno.
WO2008140419A3 (en)	2009-04-30	Pyridyl substituted pyrimidine derivatives
PL1732902T3 (pl)	2010-06-30	Pochodne nukleozydów i ich terapeutyczne zastosowanie
WO2008140421A3 (en)	2009-04-30	Heterocycloalkyl substituted pyrimidine derivatives
MY148355A (en)	2013-03-29	Crystal form of epothilone b and use in pharmaceutical compositions
CY1112245T1 (el)	2015-12-09	Ετεροαλκυλ συνδεδεμενα παραγωγα πυριμιδινης
UA93878C2 (ru)	2011-03-25	Производная бензилпиперазина, ee применение при лечении разных расстройств и фармацевтическая композиция, которая ee содержит
UA101610C2 (ru)	2013-04-25	Наночастица, которая содержит рапамицин и альбумин, в качестве противоракового агента